Two Sigma Advisers
ORMP icon

Two Sigma Advisers’s Oramed Pharmaceuticals ORMP Stock Holding History

Two Sigma Advisers’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-213,000
Closed -$456K – 2476
2025
Q1 		$456K Sell
213,000
-28,400
-12% -$65.5K ﹤0.01% 1820
2024
Q4 		$584K Sell
241,400
-14,200
-6% -$33.7K ﹤0.01% 1724
2024
Q3 		$624K Sell
255,600
-3,500
-1% -$8.53K ﹤0.01% 1615
2024
Q2 		$666K Sell
259,100
-4,400
-2% -$10.5K ﹤0.01% 1761
2024
Q1 		$769K Sell
263,500
-20,100
-7% -$56.2K ﹤0.01% 1688
2023
Q4 		$655K Buy
283,600
+118,000
+71% +$252K ﹤0.01% 1813
2023
Q3 		$432K Sell
165,600
-25,000
-13% -$78.7K ﹤0.01% 1842
2023
Q2 		$682K Sell
190,600
-254,300
-57% -$815K ﹤0.01% 1692
2023
Q1 		$970K Buy
444,900
+193,000
+77% +$613K ﹤0.01% 1646
2022
Q4 		$3.03M Sell
251,900
-79,600
-24% -$619K 0.01% 1009
2022
Q3 		$2.15M Sell
331,500
-350,300
-51% -$2.84M 0.01% 1137
2022
Q2 		$3.12M Buy
681,800
+19,800
+3% +$106K 0.01% 980
2022
Q1 		$5.73M Buy
662,000
+434,700
+191% +$4.45M 0.02% 745
2021
Q4 		$3.25M Buy
+227,300
New +$4.75M 0.01% 959

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Two Sigma Advisers's ORMP Position: Q2 2025 in Review

Two Sigma Advisers sold out of Oramed Pharmaceuticals (ORMP) in Q2 2025, closing a stake of 213,000 shares — an estimated $456K sold.

Two Sigma Advisers first reported a position in ORMP in Q4 2021 and held it in 14 quarters. The position peaked at $5.73M in Q1 2022. 47 funds tracked by Wall St. Rank hold ORMP as of Q2 2025.

  • Two Sigma Advisers reported no remaining Oramed Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 213,000 Oramed Pharmaceuticals shares in Q2 2025, an estimated $456K.
  • Two Sigma Advisers first reported a position in Oramed Pharmaceuticals in Q4 2021 and held it in 14 quarters.
  • Two Sigma Advisers's Oramed Pharmaceuticals position peaked at $5.73M in Q1 2022.
  • 47 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2025.

Based on Two Sigma Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.